Istari Oncology, Inc., a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug application (IND) for a Phase 2 clinical trial, LUMINOS-102, to investigate the efficacy and safety of PVSRIPO alone or in combination with a programmed death receptor-1 (anti-PD-1) inhibitor in patients with treatment-refractory melanoma.
Publications
Real-world outcomes of advanced melanoma patients not represented in phase III trials
Researchers sought to provide evidence on systemically treated patients with advanced melanoma not represented in phase III trials to support clinical decision?making.
Effects of exogenous hormones and reproductive factors on female melanoma: A meta-analysis
In view of inconsistent epidemiological findings concerning the effects of hormones on melanoma risk, researchers carried out a meta-analysis investigating the correlation between exogenous hormonal and reproductive factors and the risk of melanoma in women.
MRV Newsletter Issue 12, November 2020
Please follow this link to download the 12th edition of the MRV newsletter. Read More